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two back translations of the English ItchRO. Cognitive interviews with five children 
with ALGS (patient report) and five parents (observer report) were to be performed. 
Key inclusion criteria were: children aged 5-9 years with cholestatic liver disease 
(ALGS) or progressive familial intrahepatic cholestasis (PFIC), who were also expe-
riencing itching. Results: Recruitment was challenging and threatened to delay 
the clinical trial programme. Thus, recruitment was extended to include children 
who were 3-17 years of age, and in Spain and Germany, patients with alternative 
pathologies that manifested primarily with generalized pruritus were included. The 
final sample included: 15 with ALGS (France n= 5; Poland n= 5; Germany n= 3; Spain 
n= 2), 2 with PFIC (Spain), 2 with atopic dermatitis (Germany) and 1 with contact 
dermatitis (Spain). The ItchRO translations were well understood; there were no 
apparent differences in translation interpretations by disease state. ConClusions: 
Recruitment in linguistic validation projects in rare diseases can be a hurdle, yet 
patient understanding, rather than those of ‘lay people, ’ is preferable in paediatrics 
to ensure adequate interpretation, which can vary substantially across children. As a 
result patients with similar symptom and impact characteristics could be recruited 
if recruiting the primary population is likely to delay clinical trial research in rare 
diseases, where there is an urgent need for treatment.
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objeCtives: To determine NutriQoL® responsiveness and minimal clinically impor-
tant difference (MCID) in patients receiving HEN. Methods: NutriQoL®, a specific 
questionnaire, developed and validated in Spain, for the assessment of HRQoL in 
patients receiving HEN regardless of the underlying condition was administered 
to a prospective cohort from 4 Spanish hospitals. It includes 17 pairs of items of 
HEN-related HRQoL, scoring from -51 (worst HRQoL) to 51 (best HRQoL). NutriQoL® 
was completed three times within 1-month (±15 days) intervals (visit 1/visit 2/visit 
3). Responsiveness was assessed by estimating the effect size and the standard-
ized response mean between visits 1 and 3. For MCID calculation an anchor-based 
approach was performed. Interquartile range of the change in NutriQoL® from 
patients, who reported changes in their health-status (worse or better) between 
visits 2 and 3, was used. Results: A total of 86 subjects who presented clinical 
changes between visits [63% male; mean (SD) age 61 (13)] participated. Cancer was 
the main diagnosis leading to HEN prescription (66.3%). NutriQoL® scores were 16.98 
(14.57), 16.63 (14.86) and 18.92 (15.25) for visit 1, 2 and 3, respectively. Up to 78.79% of 
patients reported improvements in their HRQoL since the introduction of HEN. The 
estimated effect size and the standardized mean response between visit 1 and 3 
were 0.23 and 0.24. Regarding MCID, NutriQoL® total scores difference between visit 
2 and 3 in those patients that perceived changes in their health status was between 
-3.75 and 4.25 (interquartile range). ConClusions: NutriQoL® responsiveness is 
moderate. This may be due to the limited temporal period between visits since most 
of patients referred improvements in their condition. A difference of ±4 points on 
NutriQoL® total score regarding a previous administration demonstrates a clinical 
change that affects patients HRQoL.
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objeCtives: Treatment effects on health-related quality of life (QoL) often differ 
depending on whether they are measured prospectively (before and after treatment) 
or retrospectively (after treatment only). It is not clear which of either evaluations is 
more valid: Prospective evaluations may be biased by scale recalibration (a changed 
understanding of the response scale), and retrospective evaluations may be biased 
by recall bias (a wrong assessment of former QoL). Methods: Based on an analy-
sis of literature, we present an overview on (a) possible biases in prospective and 
retrospective measurement of QoL, (b) how these biases are named and defined in 
literature, and (c) current approaches to distinguish scale recalibration and recall 
bias. Results: The definitions of different biases are inconsistent. Many authors 
do not clearly distinguish measurement bias from true change. Furthermore, some 
consider only scale recalibration or only recall bias. There are different approaches 
for distinguishing scale recalibration and recall bias. We argue that these make too 
extensive assumptions to be valid. ConClusions: Much of the current discussion 
on the validity of prospective and retrospective QoL measurement suffers from 
unclear definitions, especially of “response shift” and “recall bias”, or from neglect-
ing one of the possible biases. We suggest more elaborate definitions for different 
types of bias, and recommend taking both kinds of bias into consideration when 
measuring change in QoL. Due to a lack of valid methods, there is not enough evi-
dence on the extent of these biases yet; therefore the best approach for outcomes 
studies might be to include both prospective and retrospective assessments. In the 
long run, valid methods need to be developed to determine the most valid method 
of QoL assessment.
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The patients are asked to complete the questionnaire at initial contact with the out-
patient clinic and at four follow-up time points; one week, and one, three, and twelve 
months post-fracture). The last inclusion date will be December 31st2014. Results: 
The hypothesis is that the QUALIOST will provide a better estimate of the impact 
of osteoporosis-related fractures on HRQoL as it contains disease-relevant aspects, 
which may not be sufficiently covered in the generic EQ-5D-5L questionnaire. We will 
develop a mapping algorithm to predict EQ-5D derived utilities for Danish fracture 
patients from the QUALIOST, which can be used in future studies, where utilities then 
may be estimated from QUALIOST results. ConClusions: Mapping from QUALIOST 
scores to EQ-5D-5L derived utilities will enable estimation of preference-based HRQoL 
utilities for patients with osteoporotic fractures.
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objeCtives: Diabetic macular edema (DME) is a serious condition occurring in 
patients with diabetic retinopathy (DR) which is a common complication of diabetes. 
Understanding not only objective measurements such as visual acuity, but also the 
patients’ perspective is important in gaining a comprehensive understanding of 
the impact of DME and its treatment on their functioning and well-being. The aim 
of this study is to understand possible measurements to investigate the impact of 
DME on health-related quality of life (HRQoL), by identifying currently available 
measurements, their ability to differentiate between DR and DME, and possible 
reasons for difficulties in measuring HRQoL specifically for DME. Methods: We 
performed a literature review on articles describing instruments of patient-reported 
outcomes (PRO) for DME. We summarized the current evidence on the usefulness of 
the instruments and whether they differentiate between DR and DME. In addition, 
we investigated possible hurdles in measuring HRQoL for DME, given the clinical 
understandings of the systemic aspects of DME. Results: We identified seven con-
dition-specific or vision-specific measurements and seven general measurements 
including generic HRQoL and utilities for possible instruments for DME. However, 
realistic use for DME appears questionable even for vision-related measurements. 
The possible reasons could be that: 1) DME is not the primary disease, 2) many of 
DME patients have comorbidities such as DR, cataracts, and DR-induced glaucoma, 
and 3) those comorbidities itself may lead to decreased visual acuity with decreased 
HRQoL. ConClusions: Evidence is limited when measuring the impacts of DME 
on diabetic patients largely due to the lack of an effective PRO instrument for DME. 
The major difficulties in developing such instruments is that DME patients have 
complex health statuses, which provides for multiple reasons in decrease of QoL 
which may not be directly due to their DME.
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objeCtives: The Behavior Rating Inventory of Executive Function Preschool Version 
(BRIEF-P) was designed to provide a better understanding of preschool children’s self-
control and problem-solving skills. It is composed of 63 items organized in five clinical 
scales which measure five aspects of executive functioning (Inhibit, Shift, Emotional 
Control, Working Memory, Plan/Organize). It is used to evaluate children aged 2-5 years 
old with a wide spectrum of developmental and acquired neurological conditions, such 
as learning disabilities, Tourette’s disorder, traumatic brain injury, attention-deficit/
hyperactivity disorder or pervasive developmental disorders/autism. The objective of 
this study was to develop the BRIEF-P in 10 languages (Afrikaans, Bulgarian, Estonian, 
Greek, Japanese, Lithuanian, Romanian, Serbian, Slovak, Ukrainian). Methods: The 
following methodology was used: (1) Clarification of concepts with the developers; (2) 
Forward and backward translation steps in each target country. Results: The transla-
tion process did not reveal any cultural issues since most of the concepts assessed 
were cross-culturally relevant. The main difficulties consisted in finding conceptual 
equivalents of the original items with strong idiomatic content or containing words 
pertaining to the same semantic field. For instance, the most problematic items were 
items 10, 23 and 50. Item 23 (Is fidgety, restless, or squirmy) raised difficulties since it was 
not always possible to find direct equivalents for all adjectives in all languages. As 
for item 50 [Acts overwhelmed or overstimulated in crowded, busy situations (such as lots of 
noise, activity, or people)], discussions focused on how to convey the differences between 
“overwhelmed” and “overstimulated”, as well as between “busy” and “crowded.” 
In all cases, issues were solved with repeated discussions with the develop-
ers. ConClusions: The cross-cultural adaptation of the BRIEF-P into 10 languages 
required an international collaboration. The involvement of the developers during 
the whole process enabled the production of conceptually equivalent and culturally 
appropriate measures.
PRM181
CHallenges in ReCRuiting Patients foR tHe linguistiC validation of 
PRo instRuMents develoPed foR RaRe diseases: a Case study WitH 
alagille syndRoMe
Kennedy C.1, Abetz-Webb L.2, Lambe J.3
1Lumena, San Diego, CA, USA, 2Patient-Centred Outcomes Assessments LTD, Macclesfield, 
Cheshire, UK, 3Mapi, Lyon, France
objeCtives: Observer and Patient Itch-reported Outcome Instruments (ItchRO) 
are electronic morning and evening diaries developed in US English to assess itch-
related symptom severity (rubbing, scratching, skin damage, sleep disturbances or 
irritability) in pediatric patients suffering from rare cholestatic liver diseases such 
as Alagille Syndrome (ALGS). Itching is a key symptom in ALGS and significantly 
impacts on a child’s daily life. This research presents the recruitment challenges 
faced during the linguistic validation of the ItchRO into French, German, Polish and 
Spanish in ALGS patients. Methods: Native translators performed two forward and 
